Could a cancer drug stop a deadly complication in transplant patients?
NCT ID NCT07614282
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug rituximab can safely clear Epstein-Barr virus (EBV) from the blood of people who have received a solid organ transplant. High levels of EBV can lead to a serious cancer called post-transplant lymphoproliferative disorder (PTLD). The trial will enroll 28 adults with EBV in their blood to see if rituximab can prevent PTLD when lowering immune-suppressing medications is not an option.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPSTEIN-BARR VIRUS (EBV) INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Video game therapy gets bedridden patients back on their feet
- Wizard game teaches transplant kids about potions (meds)
- Small study checks COVID-19 vaccine power in young cancer patients
- Researchers examine rare Post-Transplant cancer to improve future care
- Supercharged immune cells take on post-transplant viruses
- New pill takes on rare, stubborn lymphoma